September is National Childhood Obesity Awareness Month. According to the CDC, about 1 in 5 American children has obesity. These children are at a higher risk for asthma, sleep apnea, bone and joint problems, type 2 diabetes, and risk factors for heart disease such as high blood pressure. Explore our diabetes & obesity resources here: bit.ly/3POaAdP #ChildhoodObesityAwarenessMonth #ChildhoodObesityMonth #ChildhoodObesity #ObesityResearch
ALPCO’s Post
More Relevant Posts
-
What are you doing on Tuesday, November 7th? Hopefully joining us for our webinar! With GLP-1 therapies growing in popularity, there’s no better time to get a deeper understanding of how they’ll affect Type 2 diabetes and obesity care. Don’t miss our upcoming webinar to learn about the opportunities and challenges of this new class of drugs for the Type 2 diabesity epidemic: https://lnkd.in/gEHKFxEk #ChronicCare #Diabetes #Webinar
-
-
Have you registered yet? It's tomorrow! With GLP-1 therapies growing in popularity, there’s no better time to get a deeper understanding of how they’ll affect Type 2 diabetes and obesity care. Don’t miss our webinar to learn about the opportunities and challenges of this new class of drugs for the Type 2 diabesity epidemic: https://lnkd.in/gyxJyBtK #ChronicCare #Diabetes #Webinar
-
-
With GLP-1 therapies growing in popularity, there’s no better time to get a deeper understanding of how they’ll affect Type 2 diabetes and obesity care. Don’t miss our upcoming webinar to learn about the opportunities and challenges of this new class of drugs for the Type 2 diabesity epidemic: https://lnkd.in/gEHKFxEk #ChronicCare #Diabetes #Webinar
-
-
With GLP-1 therapies growing in popularity, there’s no better time to get a deeper understanding of how they’ll affect Type 2 diabetes and obesity care. Don’t miss our upcoming webinar to learn about the opportunities and challenges of this new class of drugs for the Type 2 diabesity epidemic: https://lnkd.in/gEHKFxEk #ChronicCare #Diabetes #Webinar
-
-
This #WorldObesityDay (March 4, 2023), we’re using the power of conversation to show how obesity is connected to the world around us. Obesity is often driven by forces outside of a person's control. Biological and genetic factors put some of us at greater risk. As the World Obesity Federation notes, although physical activity plays an important role in overall health and can be used in the context of comprehensive weight management interventions and prevention strategies, exercise alone is not an effective obesity treatment. VIVUS is proud to partner with the World Obesity Federation and help create awareness and action around treating this chronic disease. We are committed to advancing treatment options for obesity and offering much-needed hope to patients globally. To learn more about our work in this area please visit VIVUS.com. #WorldObesityDay #ObesityAnd #LetsTalk #WOD2024 #treatingobesity #obesitymedicine #vivusllc #weightmanagement #weightlossmedications
Improving patient quality of life
vivus.com
-
Don't forget to register today for this amazing event!!!! With GLP-1 therapies growing in popularity, there’s no better time to get a deeper understanding of how they’ll affect Type 2 diabetes and obesity care. Don’t miss our upcoming webinar to learn about the opportunities and challenges of this new class of drugs for the Type 2 diabesity epidemic: https://lnkd.in/gyxJyBtK #ChronicCare #Diabetes #Webinar
-
-
With GLP-1 therapies growing in popularity, there’s no better time to get a deeper understanding of how they’ll affect Type 2 diabetes and obesity care. Don’t miss our upcoming webinar to learn about the opportunities and challenges of this new class of drugs for the Type 2 diabesity epidemic: https://lnkd.in/gEHKFxEk #ChronicCare #Diabetes #Webinar
-
-
With GLP-1 therapies growing in popularity, there’s no better time to get a deeper understanding of how they’ll affect Type 2 diabetes and obesity care. Don’t miss our upcoming webinar to learn about the opportunities and challenges of this new class of drugs for the Type 2 diabesity epidemic: https://lnkd.in/gEHKFxEk #ChronicCare #Diabetes #Webinar
-
-
With GLP-1 therapies growing in popularity, there’s no better time to get a deeper understanding of how they’ll affect Type 2 diabetes and obesity care. Don’t miss our upcoming webinar to learn about the opportunities and challenges of this new class of drugs for the Type 2 diabesity epidemic: https://lnkd.in/gEHKFxEk #ChronicCare #Diabetes #Webinar
-
-
With GLP-1 therapies growing in popularity, there’s no better time to get a deeper understanding of how they’ll affect Type 2 diabetes and obesity care. Don’t miss our upcoming webinar to learn about the opportunities and challenges of this new class of drugs for the Type 2 diabesity epidemic: https://lnkd.in/gEHKFxEk #ChronicCare #Diabetes #Webinar
-
